Between February 10-14, 2025, the US FDA conducted an inspection to ensure compliance with US pharmaceutical manufacturing ...

GNPA spiked to 6.17%, compared with 3.88% in the previous quarter, while Net NPA up 2.5% from 0.89%, signalling asset quality ...

EBITDA fell 21.8% YoY to ₹47.7 crore, against ₹61 crore in the previous year, with EBITDA margin declining to 31.7% from 37.9 ...

Aditya Birla Fashion revenue from operations increased by 3.3% YoY to ₹4,304.7 crore as compared with ₹4,166.7 crore ...

Alembic Pharmaceuticals net profit dropped 23% YoY to ₹138.4 crore in Q3 FY25 from ₹180.4 crore in the same quarter of last ...

The contract is an EPC contract and encompasses the design, engineering, manufacturing, supply, erection, commissioning, and civil works.

The deal is aimed at improving operational efficiency, expanding capabilities, and fuel innovation in the maritime sector.

As part of the contract, debentures shall have a tenure of 3,651 days (approx. 10 years) and shall be listed on the Wholesale ...

However, the company stated that its revenue from operations registered a growth of 66.90% to ₹534.70 Crore in Q3FY25.

The revenue increased by 8% YoY to ₹11,995 crores against ₹11,066 crores in Q3 FY24 due to strong demand in the market.

At the operating level, EBITDA declined by 8% YoY to ₹177.1 crore from ₹192.4 crore in the same quarter last year.

In January 2025, passive funds also saw strong inflows, with marginal price depletion.